Gliomas are the most common tumours of the central nervous system and the most
aggressive form is glioblastoma (GBM). Despite advances in treatment, patient survival …

Immunotherapy has achieved unprecedented clinical efficacy in patients with various types
of advanced tumors; however, some patients experience delayed tumor shrinkage following …

Background Pseudoprogression is a diagnostic challenge in early posttreatment
glioblastoma. We therefore developed and validated a radiomics model using …

Simple Summary Glioblastoma is the most common and malignant primary brain tumor.
Despite intensive research for new treatments, the survival of patients has not significantly …

Glioblastoma is the most aggressive type of primary adult brain tumour. The median survival
of patients with glioblastoma remains approximately 15 months, and the 5-year survival rate …

Treatment evaluation of patients with glioblastomas is important to aid in clinical decisions.
Conventional MRI with contrast is currently the standard method, but unable to differentiate …

Pediatric brain tumors are the leading cause of childhood cancer-related death.
Immunotherapy is a powerful new approach for treating some refractory cancers; applying …

AIM To review how machine learning (ML) is applied to imaging biomarkers in neuro-
oncology, in particular for diagnosis, prognosis, and treatment response monitoring …

Gliomas, particularly glioblastoma (GBM), represent the most prevalent and aggressive
tumors of the central nervous system (CNS). Despite recent treatment advancements, patient …

Interferon regulatory factor 9 (IRF9) is an integral transcription factor in mediating the type I
interferon antiviral response, as part of the interferon-stimulated gene factor 3. However, the …